Arcus Biosciences Inc. Stock News

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people

The average of price targets set by Wall Street analysts indicates a potential upside of 151.6% in Arcus Biosciences, Inc. (RCUS). While the effectiveness of this highly sought-after metric is questio

Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people

Gilead Sciences said on Monday it has raised its stake in Arcus Biosciences to 33% and expanded its presence in the drug developer's board to three, deepening their collaboration in developing cancer

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Arcus Biosciences is developing a combination therapy of PD-1 and TIGIT inhibitors for esophagogastric cancer, showing promising efficacy in a phase 2 study. The company's most advanced molecule, domv

Stocks driving that large-cap index performance include names you've become familiar with this year, such as Nvidia Corp. NASDAQ: NVDA, Tesla Inc. NASDAQ: TSLA and Meta Platforms Inc. NASDAQ: META, bu

Arcus Biosciences, Inc. (NYSE:RCUS ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Pia Eaves - Head of Investor Relations And Strategy Terry Rosen - Co-Founder, Cha

Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with Gilead, Roche/Genentech, and AstraZeneca, and a l

Nvidia: calm before the storm There's a calm before storm ahead of today's hotly-anticipated quarterly financials, albeit Nvidia stock is up US$9.17 or 2% changing hands at US$465.75. Expectations are

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.93 per share a year ago.

Suppose you're looking for a sector that will benefit from an end to the Federal Reserve's interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $0.96 per share a year ago.